DexCom hit record profitability of 6.01% ROIC precisely when revenue growth collapsed from 15.6% to 4.2% — a transformation that has split Wall Street's greatest minds. While insiders poured $21 million into shares trading at 21% of their 52-week high, the market values this medical device pioneer at a 332% premium to treasuries despite generating its best margins ever.
The business has never been stronger operationally, yet trades at distressed valuations
Record ROIC of 6.01% and operating margins of 25.6% while stock sits at 21.27% of 52-week high.
Management's $21 million insider buying signals conviction precisely when the market has given up
Net buying of 342,775 shares after years of selling, timed with the stock's -66.3% drawdown.
The margin expansion to 25.6% represents a fundamental shift in the business model
Operating margins expanded 640 basis points even as revenue growth decelerated 1,140 basis points.
Is DexCom a growth story dying or a profit machine being born?
A wonderful business temporarily mispriced by growth deceleration fears
Trading at 48% discount to DCF value despite record 25.6% margins and $1.08B free cash flow.
An overvalued stalwart masquerading as a growth stock
24x P/E ratio unjustifiable for 4.2% revenue growth — fast grower valuation on stalwart performance.
Does 1.04% earnings yield versus 4.33% treasuries doom any bull case?
The -4.32% spread is justified by transformation and 6.09% implied growth
ROIC surged from -9.72% to 6.01% over seven years while market prices reasonable 6.09% growth.
No margin of safety exists when earnings yield is one-quarter of risk-free rates
Despite 92.1% upside to DCF, the 1.04% earnings yield offers no cushion against 4.33% treasuries.
The 45-point spread reveals a fundamental disagreement about whether DexCom is transitioning to sustainable profitability or simply decelerating toward mediocrity. Lynch stands alone seeing overvaluation where others see opportunity.
All five frameworks miss the buyback disaster — DexCom torched $500 million repurchasing shares at $128.02 that now trade at $62.22, a -51.4% destruction of shareholder capital. This management misstep raises questions about capital allocation judgment even as insiders buy personally.
When a company's ROIC hits an all-time high of 6.01% in the same quarter its revenue growth crashes to 4.2%, is it becoming a better business or just a slower one?